Apoptosis: A Strategy for Psoriasis

Abbas A.K. , Lichtman A.H. , Pober J.S. Cellular and Molecular Immunology. Philadelphia, W.B. Saunders Company 2000, pp 130–491

Godar D.E. Light and Death: Photons and Apoptosis. J Invest Dermatol. Symposium Porceedings. Photobiology 1999; 4(1): 17–23.

Pope R.M. Apoptosis as a therapeutic tool in rheumatoid arthritis. Immunology 2002; 2: 527–535.

Nickoloff B.J. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104–1110.

Gottlieb AB. Product development for Psoriasis: Clinical Challenges and Opportunities, in Psoriasis, edited by Roenigk H. , and Maibach H. , Third Edition, Marcel Dekker, Inc., NY, NY, 1998, 421–433.

Gottlieb A.B. Psoriasis: Immunopathology and Immunomodulation, Dermatologic Clinics 19: 649–657, 2001.

Cather J. , Menter A. Novel Therapies for Psoriasis. Am J Clin Dermatol 2002; 3(3): 159–173.

Ellis C.N. , Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248–256.

Granstein R.D. New treatments for psoriasis. N Engl J Med 2001; 345: 284–287.

Krutmann J. , Morita A. Mechanisms of Ultraviolet (UV) B and UVA Phototherapy. J Invest Dermatol, 1999; 4: 70–72.

Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1–23.

Mrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001; 26: 362–367.

Singri P. , West D.P. , Gordon K.B. Biologic Therapy for Psoriasis. The new therapeutic frontier. Arch Dermatol 2002. 138: 657–662.

Berlinger J. Adaptations and Cell Injury. David Geffen School of Medicine at UCLA, Department of Pathology and Laboratory Medicine 2003, pp 23–27.

Gottlieb S.L. , Gilleaudeau P. , Johnson R. , Estes L. , Woodworth T.G. , Gottlieb A.B. , Krueger J.G. : Response of psoriasis to a lymphocyte-selective toxin (DAB₃₈₉ IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1: 442–447, 1995

Manggau M. , Kim D.S. , Ruwisch L. . 1alpha25-Dihydroxyvitamin D3 Protects Human Keratincytes from Apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol 2001; 117: 1241–1248.

Iyer A. , Yamauchi P. , Lowe N.J. . Etanercept for sever psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146: 118–121.

Van Deventer S.J.H. Transmembrane TNF-α, Induction of Apoptosis, and the Efficacyof TNF-targeting Therapies in Crohn's Disease. Gastroenterology 2001; 121: 1242–1245.

LaDuca J.R. , Gaspari A.A. Targeting Tumour Necrosis Factor Alpha: New Drugs Used to Modulate Inflammatory Disease. Dermatologic Clinics 2001; 19: 1–21.

Girolomoni G. , Abeni D. Anti-Tumor Necrosis Factor-α Therapy in Psoriatic Arthritis and Psoriasis. Arch Dermatol 2001; 137.

Greaves M.W. The immunopharmacology of skin inflammation: the future is already here! Br J Dermatol 2000; 143: 47–52.

Kirby B. , Griffiths C.E.M. Psoriasis: the future. Br J Dermatol 2001; 144: 37–43.

Kondo S. , Hozumi Y. Comparative inhibitory effects of vitamin D₃ and an analogue on normal and psoriatic epidermis in organ culture. Arch Dermatol 2000; 292: 550–555.

McCarty M.F. Upregulation of lymphocyte apoptosis as a strategy for preventing and treating autoimmune disorders: a role for whole-food vegan diets, fish oil and dopamine agonists. Med Hypotheses 2000; 57: 258–275.

Chou C.T. , Yang J.S. , Lee M.R. Apoptosis in rheumatoid arthritis - expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. J Pathol 2001; 193: 110–116.